Oppenheimer Upgrades Alnylam Pharmaceuticals to Outperform, Announces $200 Price Target
Oppenheimer analyst Leland Gershell upgrades Alnylam Pharmaceuticals (NASDAQ:ALNY) from Perform to Outperform and announces $200 price target.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $200
Chardan Capital analyst Keay Nakae maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $190 to $200.
SVB Leerink Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $108
SVB Leerink analyst Mani Foroohar maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Market Perform and raises the price target from $104 to $108.
Alnylam’s Founding CEO John Maraganore To Exit The Company
In a surprise announcement, Alnylam Pharmaceuticals Inc’s (NASDAQ:ALNY) founding CEO John Maraganore will hand the reins to current president Yvonne Greenstreet at…
Biotech Reporter Adam Feuerstein Tweets ‘$ALNY down big on Maraganore’s exit.’
https://twitter.com/adamfeuerstein/status/1453712665101090828?s=20
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: